Peptides vs Small Molecules: What Actually Differs in the Lab

Peptides vs small molecules: two kinds of compound

A small molecule is a compact organic compound with a structure of its own, designed or discovered as a whole. A peptide is a chain of amino acids joined by amide bonds, and its identity is its sequence. Glucagon, for example, is 29 residues long and weighs about 3,483 g/mol by our calculation from its UniProt sequence; the 5-Amino-1MQ cation weighs about 159 g/mol.

Size is the obvious difference, but architecture explains more. A peptide is a modular polymer: it is made by repeating one kind of reaction, its impurities tend to be near-copies of itself, and its flexible chain can contact a broad patch of protein surface. A small molecule is bespoke: it needs its own synthetic route, its impurities are usually different compounds, and its compact shape suits a defined pocket. Most of the contrasts below follow from that.

What makes a molecule small: the rule of five

We found no formal chemical definition of a small molecule. The working definition comes from drug discovery, and its most familiar form is the “rule of 5” published by Christopher Lipinski and colleagues in 1997. Poor absorption or permeation, they wrote, is more likely “when there are more than 5 H-bond donors, 10 H-bond acceptors, the molecular weight (MWT) is greater than 500 and the calculated Log P (CLogP) is greater than 5”.

The rule concerns absorption and permeation, not activity, and it is a heuristic rather than a boundary. Reviewing peptide drugs in 2023, Otvos and Wade observe that if developers had followed the “now widely criticized” rule, “peptide drugs would have never made the market”.

Peptides fall outside it at once. Glucagon weighs about seven times the 500 threshold, and because every backbone amide bond except one made to proline carries an N–H group, hydrogen-bond donors pile up with each residue. Oral absorption is irrelevant to a reagent used in vitro, but the same properties return as the question of whether a compound crosses a cell membrane, which matters in live-cell assays.

Where a peptide ends and a protein begins

For a refresher on what peptides are: they are chains of amino acids, and proteins are longer ones. Where the line falls depends on who draws it.

US FDA regulations on biological products (21 CFR 600.3) define a protein as “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size”, counting together chains that associate as they do in nature. Under that wording glucagon, at 29 residues, falls below the line, while insulin, two chains of 21 and 30 residues joined by disulfide bonds, counts as 51 and so is a protein.

The IUPAC Gold Book is looser. Its entry for proteins reads: “Naturally occurring and synthetic polypeptides having molecular weights greater than about 10000 (the limit is not precise).” Some reviews use 50 residues instead: Otvos and Wade, for example, attribute that figure to current FDA guidelines, although the regulation quoted above says 40.

No definition marks a change in chemistry at a particular count. What does change with length is the difficulty of synthesis: Wang and colleagues call Fmoc solid-phase synthesis of peptides under 50 residues “relatively routine” and longer chains still challenging. The FDA definition is a US regulatory term for biological products, and this article makes no claim about how any laboratory reagent is classified.

How each is made

A small molecule is made by a route designed for one structure: a sequence of different reactions, each chosen for the bond it must form. Brown and Boström found that the most frequently used reactions in medicinal chemistry were amide bond formation, Suzuki–Miyaura coupling and nucleophilic aromatic substitution — so the bond that links every peptide is also one of the medicinal chemist’s staples.

A peptide is made by repetition. In solid-phase peptide synthesis, introduced by Merrifield in 1963, the first amino acid is anchored to a resin and the chain grows one residue at a time: free the growing end of its protecting group, couple the next protected amino acid, and repeat. The chain is then cleaved from the resin and purified.

Repetition compounds small losses. If each coupling left one chain in a hundred unextended, a 40-residue synthesis would end with only about two-thirds of its chains full length (0.99 to the 39th power is about 0.68, by our arithmetic). Most of the rest would be near-copies missing a residue or two — deletion sequences — which is why peptide quality control looks so different.

How identity and purity are checked

The guidelines written for medicines show the split. ICH Q6A, on chemical drug substances, says it may apply to “synthetic peptides of low molecular weight” but that “it is not sufficient to adequately describe specifications of higher molecular weight peptides and polypeptides”. ICH Q6B, for biotechnological products, “does not cover antibiotics, synthetic peptides and polypeptides”. Larger synthetic peptides fall between the two. Both are pharmaceutical frameworks; we cite them for the questions they ask, not as a statement of which rules govern a research reagent.

Two consequences stand out. A peptide’s mass confirms its composition, not its order: a scrambled sequence weighs exactly the same, so a correct mass is necessary evidence, not proof. And a peptide powder is not all peptide. Because trifluoroacetic acid (TFA) is used for cleavage and purification, Sikora and colleagues note, “the cationic peptides are obtained as trifluoroacetate salts”, and they list residual water among the factors quality control must measure. Both matter when a weighed amount becomes a molar concentration.

Stability, solubility and handling

Small molecules degrade through the chemistry of their particular functional groups, and as solids they raise a further question. As ICH Q6A puts it, “Some new drug substances exist in different crystalline forms that differ in their physical properties.” Lipinski’s group wrote that solubility calculations in the development setting are difficult because of polymorphism.

A peptide’s weak points are written into its sequence. Nugrahadi and colleagues define chemical instability as “processes that alter the peptide by creating or breaking covalent bonds”, including oxidation, hydrolysis and deamidation: asparagine and glutamine are prone to deamidation, while methionine and cysteine are “particularly susceptible to oxidation”. Physical instability adds aggregation, which can end in precipitation, and peptides “are often unstable in aqueous solutions”. A methionine-containing chain therefore has an oxidation route that a methionine-free chain lacks, and the same powder can behave very differently once dissolved. Our guide to how peptides degrade covers each pathway.

How each reaches its target

Small molecules usually act by occupying a defined pocket, such as an enzyme’s active site. The patent describing 5-Amino-1MQ includes a schematic of the compound’s predicted binding mode in the substrate-binding site of the enzyme NNMT. Their small size also lets many small molecules cross cell membranes to intracellular targets, as Wang and colleagues note.

Peptides work at a different scale. Protein–protein interfaces usually cover 1,500–3,000 Ų, the same review notes, while small molecules cover 300–1,000 Ų; a peptide’s size and flexible backbone suit those broad surfaces. The trade-off is access. Peptides “are generally unable to cross the cell membrane to target intracellular targets”, and in a 2018 analysis the review cites, more than 90% of peptides in active clinical development were aimed at extracellular targets.

Many of those are G protein-coupled receptors. “Many endogenous peptides activate G protein-coupled receptors (GPCRs)”, Davenport and colleagues write in a 2020 review that counted nearly 50 approved GPCR peptide drugs; our explainer on how peptide receptors work covers the mechanics. The pattern seen in peptide drugs vs small molecule drugs carries into assay design: a peptide aimed at an intracellular protein in live cells faces a delivery problem that a small molecule may not, while a small molecule may struggle to block a broad protein–protein interface.

Why a peptide catalogue lists non-peptides

Research questions do not respect chemical classes. A laboratory studying a metabolic pathway may want a peptide acting on a cell-surface receptor and a small molecule blocking an enzyme inside the cell, so a catalogue organized by research area carries both. 5-Amino-1MQ, a small-molecule NNMT inhibitor, is the clearest example in ours: its developers’ patent refers to “the NNMT inhibitor 5-amino-1MQ”, and chemically it is 5-amino-1-methylquinolinium, with no amino acid in it.

That changes what a certificate has to show. There is no sequence to confirm. The cation, C₁₀H₁₁N₂⁺, weighs about 159 g/mol by our calculation, so mass spectrometry finds it at low mass without the charge-state series of larger peptides, and a structure-specific test replaces the sequence check. Because its ring nitrogen is permanently charged, it always comes with a counter-ion. The patent describes the iodide salt, about 286 g/mol by our calculation, of which iodide is more than 40%, so whether an amount refers to salt or cation matters just as counter-ions do for peptides.

What’s established and what isn’t

Choosing compounds for in-vitro work in Canada

Whether you order from us or from another supplier, the small molecule vs peptide distinction tells you what a compound’s paperwork should contain:

• Identify the class first. A sequence or a structure, in a compound’s research guide or in a database such as PubChem, settles whether it is a peptide or a small molecule.
• For a peptide, look for the full sequence, any end caps, the expected mass and the salt form.
• For a small molecule, look for the structure or a systematic name, the salt form and a structure-specific identity test.
• Do molar arithmetic on the right basis. Counter-ions and water are part of what you weigh.
• Ask when a listing is silent. Our Contact page handles documentation and product questions. We are a supplier too, so hold our listings to the same standard as anyone else’s.

Pure Peptides Canada is a Canadian-owned supplier based in Toronto, established in 2023. Prices are in Canadian dollars, and orders ship tracked from inside Canada to every province and territory. Identity and purity data describe a reagent; they say nothing about suitability for any use outside the laboratory.

Peptides and small molecules in our catalogue

Our catalogue carries both: peptides such as BPC-157 and GHK-Cu, and non-peptides such as the small-molecule NNMT inhibitor 5-Amino-1MQ and the coenzyme NAD+. Janoshik test reports for all four are listed on our Lab Testing page.

BPC-15715-amino-acid research peptideView product GHK-CuCopper tripeptideView product 5-Amino-1MQSmall-molecule NNMT inhibitorView product NAD+Coenzyme, not a peptideView product

Frequently asked questions